Search Results
-
Description Mouse MonoclonalApplications IHC-PReactivity HuSummary Highly recommended for IHC-P in human tissues.
$439500 μl$299100 μl -
Description Mouse MonoclonalApplications IHC-PReactivity HuSummary Highly recommended for IHC-P in human tissues.
$629500 μl$299100 μl -
Description Mouse MonoclonalApplications IHC-PReactivity HuSummary Highly recommended for IHC-P in human tissues.
$629500 μl$299100 μl -
Description Mouse MonoclonalApplications WB ICC/IF IHC-P FCM IP Activation Neutralizing /InhibitionReactivity Hu, Goat, Sheep, Chmp$419100 μg -
Description Armenian Hamster MonoclonalApplications WB ICC/IF IHC-Fr FCM IP Activation Depletion Neutralizing /InhibitionReactivity Ms$319250 μg
-
$419100 μl$16925 μl
-
$419100 μg
-
$419100 μl$16925 μl
-
Description Armenian Hamster MonoclonalApplications WB ICC/IF IHC-Fr FCM IP Activation Depletion Neutralizing /InhibitionReactivity Ms
Summary The complete 145-2C11 antibody is commonly used to stimulate T cells in vitro however, when used in vivo activation of resting T cells results in cytokine release and toxicity caused by Ab-mediated cross-linking of T cells and Fcγ receptor-bearing cells. To avoid these complications non-Fc receptor binding F(ab’)2 fragments of the 145-2C11 antibody are commonly used. This non-FcR-binding anti-CD3 induces apoptosis of Ag-activated T cells in vivo by allowing durable expression of the TCR and sustained signaling. Foxp3+ Tregs have been shown to be resistant to CD3 antibody-mediated depletion.
$339500 μg -
Description Rat MonoclonalApplications IHC-Fr FCM IP DepletionReactivity Ms$129100 μg
HistoMAX
Orthogonal